Germany · Delayed Price · Currency is EUR OncoTherapy Science Statistics
Total Valuation
FRA:30O has a market cap or net worth of EUR 43.34 million. The enterprise value is 31.36 million.
| Market Cap | 43.34M |
| Enterprise Value | 31.36M |
Important Dates
The last earnings date was Friday, February 6, 2026.
| Earnings Date | Feb 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 376.64M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +21.55% |
| Shares Change (QoQ) | +10.90% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 344.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.18 |
| PB Ratio | 3.73 |
| P/TBV Ratio | 3.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.55 |
| EV / Sales | 7.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.53
| Current Ratio | 8.53 |
| Quick Ratio | 7.97 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -794.03 |
Financial Efficiency
Return on equity (ROE) is -59.41% and return on invested capital (ROIC) is -33.46%.
| Return on Equity (ROE) | -59.41% |
| Return on Assets (ROA) | -26.73% |
| Return on Invested Capital (ROIC) | -33.46% |
| Return on Capital Employed (ROCE) | -36.16% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 90,613 |
| Profits Per Employee | -101,824 |
| Employee Count | 47 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 14.20 |
Taxes
In the past 12 months, FRA:30O has paid 10,864 in taxes.
| Income Tax | 10,864 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -43.40% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.12 |
| Relative Strength Index (RSI) | 50.13 |
| Average Volume (20 Days) | 3 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:30O had revenue of EUR 4.26 million and -4.79 million in losses. Loss per share was -0.02.
| Revenue | 4.26M |
| Gross Profit | -2.65M |
| Operating Income | -4.31M |
| Pretax Income | -4.77M |
| Net Income | -4.79M |
| EBITDA | n/a |
| EBIT | -4.31M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 11.87 million in cash and n/a in debt, with a net cash position of 11.87 million.
| Cash & Cash Equivalents | 11.87M |
| Total Debt | n/a |
| Net Cash | 11.87M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 11.61M |
| Book Value Per Share | 0.03 |
| Working Capital | 11.66M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -62.12%, with operating and profit margins of -101.28% and -112.37%.
| Gross Margin | -62.12% |
| Operating Margin | -101.28% |
| Pretax Margin | -112.12% |
| Profit Margin | -112.37% |
| EBITDA Margin | n/a |
| EBIT Margin | -101.28% |
| FCF Margin | n/a |
Dividends & Yields
FRA:30O does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.55% |
| Shareholder Yield | -21.55% |
| Earnings Yield | -11.04% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:30O has an Altman Z-Score of -2.59 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.59 |
| Piotroski F-Score | 2 |